1. Crystalline form I hydrochloride monohydrate (R) -7-chloro-N- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide, characterized by an X-ray powder diffractogram for containing peaks expressed as 2Θ at one or both 17.48 and 20.58 ± 0.20 degrees as measured relative to the inner standarta.2 silicon. The crystalline form I according to claim 1, characterized by an X-ray powder diffraction pattern for additionally comprising at least one peak expressed as 2Θ at 4.50, 9.04, 14.60, 15.14, 15.80, 16 60, 18.16, 18.44, 19.48, 21.74, and 25.46 ± 0.20 degrees as measured relative to the inner standarta.3 silicon. The crystalline form I according to claim 2, characterized by an X-ray powder diffraction pattern in further comprising at least two peaks expressed as 2Θ at 4.50, 9.04, 14.60, 15.14, 15.80, 16 60, 18.16, 18.44, 19.48, 21.74 and 25.46 ± 0.20 degrees as measured relative to the inner standarta.4 silicon. The crystalline form I according to claim 2, characterized by an X-ray powder diffraction pattern for additionally comprising at least four peaks expressed as 2Θ at 4.50, 9.04, 14.60, 15.14, 15.80, 16 60, 18.16, 18.44, 19.48, 21.74 and 25.46 ± 0.20 degrees as measured relative to the inner standarta.5 silicon. The crystalline form I according to claim 2, characterized by an X-ray powder diffraction pattern for additionally comprising at least six peaks expressed as 2Θ at 4.50, 9.04, 14.60, 15.14, 15.80, 16 60, 18.16, 18.44, 19.48, 21.74 and 25.46 ± 0.20 degrees as measured relative to the inner standarta.6 silicon. The crystalline form I according to claim 2, characterized by an X-ray powder diffraction pattern for additionally comprising at least eight peaks expressed as 2Θ etc.
